DXS International plc Director/Pdmr Shareholding

 
TIDMDXSP 
 

DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the "Company"), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 4 December 2023 Mr Bob Sutcliffe purchased a total of 400,000 Ordinary Shares in the Company at a price of 2.5p per share on behalf of himself and others.

Mr Sutcliffe's interest in the transaction was acquiring 180,000 Ordinary Shares. He has also transferred 200,000 DXS shares to his adult daughters. Following these transactions Mr Sutcliffe and his wife's interest in DXS Ordinary Shares is 833,386 Ordinary Shares representing 1.3% of the issued share capital of the Company.

 
     Details of the person discharging managerial responsibilities 
1     / person closely associated 
---  ----------------------------------------------------------------------- 
a)   Name                                Robert Sutcliffe 
---  ----------------------------------  ----------------------------------- 
2    Reason for the notification 
---  ----------------------------------------------------------------------- 
a)   Position/status                     Chairman 
---  ----------------------------------  ----------------------------------- 
     Initial notification 
b)    /Amendment                         Initial 
---  ----------------------------------  ----------------------------------- 
     Details of the issuer, emission allowance market participant, 
3     auction platform, auctioneer or auction monitor 
---  ----------------------------------------------------------------------- 
a)   Name                                DXS INTERNATIONAL PLC 
---  ----------------------------------  ----------------------------------- 
b)   LEI                                 2138001R1KEUWTXEVJ44 
---  ----------------------------------  ----------------------------------- 
     Details of the transaction(s): section to be repeated for 
      (i) each type of instrument; (ii) each type of transaction; 
      (iii) each date; and (iv) each place where transactions 
4     have been conducted 
---  ----------------------------------------------------------------------- 
     Description of the financial 
      instrument, type of 
a)    instrument                         Ordinary Shares of 0.33p each 
--- 
 
     Identification code                 ISIN GB00B2Q6HZ92 
 
b)   Nature of the transaction           Issue of new shares 
---  ----------------------------------  ----------------------------------- 
c)   Price(s) and volume(s) 
---                                       ---------------  --------------- 
                                          Price(s)            Volume(s) 
---                                       ---------------  --------------- 
   2.5p                                                            180,000 
   ------------------------------------------------------  --------------- 
 
d)   Aggregated information 
--- 
 
 - Aggregated volume 
 
 - Price 
 
e)   Date of the transaction             4 December 2023 
---  ----------------------------------  ----------------------------------- 
f)   Place of the transaction            Aquis Stock Exchange 
---  ----------------------------------  ----------------------------------- 
 

The Directors of DXS International plc accept responsibility for this announcement.

Enquiries:

 
David Immelman (Chief Executive)            01252 719800 
 DXS International plc             [e-mail] 
Wrecclesham House 
 Wrecclesham Road 
 Farnham 
 Surrey 
 GU10 4PS 
www.dxs-systems.co.uk 
 
 
Corporate Advisor 
David Papworth 
 City & Merchant    0207 101 7676 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

(END) Dow Jones Newswires

December 05, 2023 11:00 ET (16:00 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.